Supplement_Table_S3 – Supplemental material for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Supplemental Material, Supplementary_Material_revised_Oct.10 - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

C. Cameron (6161996)
C. Druchok (6161999)
B. Hutton (3407222)
S. McElligott (6162002)
S. Nair (2497861)
A. Schubert (1703323)
A. Situ (6162005)
A. Varu (6162008)
R. Villacorta (6162011)

April 2019

Supplemental Material, Supplementary_Material_revised_Oct.10 for Guselkumab for the Treatment of Mod...

Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies

Alan Menter (43963)
Jennifer C. Cather (5003165)
Michael Jarratt (5003162)
Xiangyi Meng (2899556)
Adriana Guana (5003027)
Judit Nyirady (806865)

March 2018

Article full text The full text of this article can be found here....

Table_1_Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis.DOCX

Juan José Alegre-Sancho (15457829)
Victoria Núñez-Monje (15457790)
Cristina Campos-Fernández (15457793)
Isabel Balaguer-Trull (15457796)
Montserrat Robustillo-Villarino (827217)
Marta Aguilar-Zamora (15457799)
Marta Garijo-Bufort (15457802)
Teresa Pedraz-Penalva (17415501)
Carolina Peña-González (15457808)
Isabel de la Morena (15457811)
Diego Bedoya-Sanchís (15457814)
Liliya Yankova-Komsalova (15457817)
Arantxa Conesa-Mateos (15457820)
Anna Martinez-Cristóbal (17415504)
Francisco Javier Navarro-Blasco (15457823)
Jose Miguel Senabre-Gallego (17415507)
Francisca Sivera (5079833)

November 2023

IntroductionPsoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disease. Secukinum...

Supplement_Table_S1 – Supplemental material for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Tzong-Yun Ger (6599690)
Yu-Huei Huang (6599693)
Rosaline Chung-yee Hui (6599696)
Tsen-Fang Tsai (799942)
Hsien-Yi Chiu (799936)

April 2019

Supplemental material, Supplement_Table_S1 for Effectiveness and safety of secukinumab for psoriasis...

Supplement_Table_S2 – Supplemental material for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Tzong-Yun Ger (6599690)
Yu-Huei Huang (6599693)
Rosaline Chung-yee Hui (6599696)
Tsen-Fang Tsai (799942)
Hsien-Yi Chiu (799936)

April 2019

Supplemental material, Supplement_Table_S2 for Effectiveness and safety of secukinumab for psoriasis...

Supplement_Table_S4 – Supplemental material for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Tzong-Yun Ger (6599690)
Yu-Huei Huang (6599693)
Rosaline Chung-yee Hui (6599696)
Tsen-Fang Tsai (799942)
Hsien-Yi Chiu (799936)

April 2019

Supplemental material, Supplement_Table_S4 for Effectiveness and safety of secukinumab for psoriasis...

Supplemental__Figure_1 – Supplemental material for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Tzong-Yun Ger (6599690)
Yu-Huei Huang (6599693)
Rosaline Chung-yee Hui (6599696)
Tsen-Fang Tsai (799942)
Hsien-Yi Chiu (799936)

April 2019

Supplemental material, Supplemental__Figure_1 for Effectiveness and safety of secukinumab for psoria...

Table S1 -Supplemental material for Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis

Jingjing Lv (5276036)
Dongmei Zhou (786550)
Yan Wang (15435)
Jingxia Zhao (5276045)
Zhaoxia Chen (5276039)
Jinchao Zhang (1324296)
Tingting Di (5276042)
Jing Hu (41899)
Bo Li (112195)
Ping Li (31981)
Feng Huang (62988)

May 2018

Supplemental material, Table S1 for Quantitative evaluation to efficacy and safety of therapies f...

Supplement_1_-_June_8_-_JCMS – Supplemental material for Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users

Arvin Ighani (5196215)
Ashley M. Yu (6399680)
Vijay K. Sandhu (6399683)
Benjamin Barankin (6399686)
Morris F. Manolson (5518172)

February 2019

Supplemental material, Supplement_1_-_June_8_-_JCMS for Satisfaction and Awareness of Systemic Psori...

Supplemental material for "Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2)"

Lebwohl, M (via Mendeley Data)

September 2019

Supplemental material for Lebwohl et al, "Tildrakizumab Efficacy and Safety Are Not Altered by Metab...

Supplemental Table 1 for: Real-world trends in biologic, oral systemic and phototherapy in United States patients with psoriasis or psoriatic arthritis

Singh, P

Supplemental Table 1 for "Real-world trends in biologic, oral systemic and phototherapy in United St...

Supplemental Material - Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data

Jamie L. W. Rhoads (17603501)
William N. Malatestinic (9435331)
Russel Burge (3556160)
Michael L. Ganz (8429814)
Kristina C. Duffin (17603504)

December 2023

Supplemental Material for Factors Associated With Treatment Escalation for Psoriasis: An Analysis of...

Additional file 1: of Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

A. Deodhar (6660410)
P. Mease (6660413)
I. McInnes (6660416)
X. Baraliakos (6660419)
K. Reich (76387)
A. Blauvelt (6660422)
C. Leonardi (6660425)
B. Porter (6660428)
A. Das Gupta (6660431)
A. Widmer (4069864)
L. Pricop (6660434)
T. Fox (2830598)

May 2019

Table S1. EAIR for Candida infection related preferred terms. Table S2. Summary of secukinumab safet...

Supplemental material for JAAD publication titled: Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a Phase III open-label, randomized, multicenter study

Magnolo, N (via Mendeley Data)

July 2020

Supplemental material for JAAD publication titled: "Secukinumab treatment demonstrated high efficac...

Supplemental material for JAAD publication titled: A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results"

Borah, B (via Mendeley Data)

September 2021

Supplemental material for JAAD publication titled: "A phase III open-label, randomized multicenter ...

Supplemental Material, Supplementary_Material_revised_Oct.10 - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

C. Cameron (6161996)
C. Druchok (6161999)
B. Hutton (3407222)
S. McElligott (6162002)
S. Nair (2497861)
A. Schubert (1703323)
A. Situ (6162005)
A. Varu (6162008)
R. Villacorta (6162011)

April 2019

Supplemental Material, Supplementary_Material_revised_Oct.10 for Guselkumab for the Treatment of Mod...

Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies

Alan Menter (43963)
Jennifer C. Cather (5003165)
Michael Jarratt (5003162)
Xiangyi Meng (2899556)
Adriana Guana (5003027)
Judit Nyirady (806865)

March 2018

Article full text The full text of this article can be found here....

Table_1_Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis.DOCX

Juan José Alegre-Sancho (15457829)
Victoria Núñez-Monje (15457790)
Cristina Campos-Fernández (15457793)
Isabel Balaguer-Trull (15457796)
Montserrat Robustillo-Villarino (827217)
Marta Aguilar-Zamora (15457799)
Marta Garijo-Bufort (15457802)
Teresa Pedraz-Penalva (17415501)
Carolina Peña-González (15457808)
Isabel de la Morena (15457811)
Diego Bedoya-Sanchís (15457814)
Liliya Yankova-Komsalova (15457817)
Arantxa Conesa-Mateos (15457820)
Anna Martinez-Cristóbal (17415504)
Francisco Javier Navarro-Blasco (15457823)
Jose Miguel Senabre-Gallego (17415507)
Francisca Sivera (5079833)

November 2023

IntroductionPsoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disease. Secukinum...

Supplement_Table_S1 – Supplemental material for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Tzong-Yun Ger (6599690)
Yu-Huei Huang (6599693)
Rosaline Chung-yee Hui (6599696)
Tsen-Fang Tsai (799942)
Hsien-Yi Chiu (799936)

April 2019

Supplemental material, Supplement_Table_S1 for Effectiveness and safety of secukinumab for psoriasis...

Supplement_Table_S2 – Supplemental material for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Tzong-Yun Ger (6599690)
Yu-Huei Huang (6599693)
Rosaline Chung-yee Hui (6599696)
Tsen-Fang Tsai (799942)
Hsien-Yi Chiu (799936)

April 2019

Supplemental material, Supplement_Table_S2 for Effectiveness and safety of secukinumab for psoriasis...

Supplement_Table_S4 – Supplemental material for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Tzong-Yun Ger (6599690)
Yu-Huei Huang (6599693)
Rosaline Chung-yee Hui (6599696)
Tsen-Fang Tsai (799942)
Hsien-Yi Chiu (799936)

April 2019

Supplemental material, Supplement_Table_S4 for Effectiveness and safety of secukinumab for psoriasis...

Supplemental__Figure_1 – Supplemental material for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Tzong-Yun Ger (6599690)
Yu-Huei Huang (6599693)
Rosaline Chung-yee Hui (6599696)
Tsen-Fang Tsai (799942)
Hsien-Yi Chiu (799936)

April 2019

Supplemental material, Supplemental__Figure_1 for Effectiveness and safety of secukinumab for psoria...

Table S1 -Supplemental material for Quantitative evaluation to efficacy and safety of therapies for psoriasis: A network meta-analysis

Jingjing Lv (5276036)
Dongmei Zhou (786550)
Yan Wang (15435)
Jingxia Zhao (5276045)
Zhaoxia Chen (5276039)
Jinchao Zhang (1324296)
Tingting Di (5276042)
Jing Hu (41899)
Bo Li (112195)
Ping Li (31981)
Feng Huang (62988)

May 2018

Supplemental material, Table S1 for Quantitative evaluation to efficacy and safety of therapies f...

Supplement_1_-_June_8_-_JCMS – Supplemental material for Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users

Arvin Ighani (5196215)
Ashley M. Yu (6399680)
Vijay K. Sandhu (6399683)
Benjamin Barankin (6399686)
Morris F. Manolson (5518172)

February 2019

Supplemental material, Supplement_1_-_June_8_-_JCMS for Satisfaction and Awareness of Systemic Psori...

Supplemental material for "Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2)"

Lebwohl, M (via Mendeley Data)

September 2019

Supplemental material for Lebwohl et al, "Tildrakizumab Efficacy and Safety Are Not Altered by Metab...

Supplemental Table 1 for: Real-world trends in biologic, oral systemic and phototherapy in United States patients with psoriasis or psoriatic arthritis

Singh, P

Supplemental Table 1 for "Real-world trends in biologic, oral systemic and phototherapy in United St...

Supplemental Material - Factors Associated With Treatment Escalation for Psoriasis: An Analysis of Electronic Health Records Data

Jamie L. W. Rhoads (17603501)
William N. Malatestinic (9435331)
Russel Burge (3556160)
Michael L. Ganz (8429814)
Kristina C. Duffin (17603504)

December 2023

Supplemental Material for Factors Associated With Treatment Escalation for Psoriasis: An Analysis of...

Additional file 1: of Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

A. Deodhar (6660410)
P. Mease (6660413)
I. McInnes (6660416)
X. Baraliakos (6660419)
K. Reich (76387)
A. Blauvelt (6660422)
C. Leonardi (6660425)
B. Porter (6660428)
A. Das Gupta (6660431)
A. Widmer (4069864)
L. Pricop (6660434)
T. Fox (2830598)

May 2019

Table S1. EAIR for Candida infection related preferred terms. Table S2. Summary of secukinumab safet...

Supplemental material for JAAD publication titled: Secukinumab treatment demonstrated high efficacy and safety in pediatric patients with moderate to severe plaque psoriasis: 24 Week results from a Phase III open-label, randomized, multicenter study

Magnolo, N (via Mendeley Data)

July 2020

Supplemental material for JAAD publication titled: "Secukinumab treatment demonstrated high efficac...

Supplemental material for JAAD publication titled: A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results"

Borah, B (via Mendeley Data)

September 2021

Supplemental material for JAAD publication titled: "A phase III open-label, randomized multicenter ...

Supplemental Material, Supplementary_Material_revised_Oct.10 - Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis During Induction Phase: A Systematic Review and Network Meta-Analysis

C. Cameron (6161996)
C. Druchok (6161999)
B. Hutton (3407222)
S. McElligott (6162002)
S. Nair (2497861)
A. Schubert (1703323)
A. Situ (6162005)
A. Varu (6162008)
R. Villacorta (6162011)

April 2019

Supplemental Material, Supplementary_Material_revised_Oct.10 for Guselkumab for the Treatment of Mod...

Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies

Alan Menter (43963)
Jennifer C. Cather (5003165)
Michael Jarratt (5003162)
Xiangyi Meng (2899556)
Adriana Guana (5003027)
Judit Nyirady (806865)

March 2018

Article full text The full text of this article can be found here....

Table_1_Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis.DOCX

Juan José Alegre-Sancho (15457829)
Victoria Núñez-Monje (15457790)
Cristina Campos-Fernández (15457793)
Isabel Balaguer-Trull (15457796)
Montserrat Robustillo-Villarino (827217)
Marta Aguilar-Zamora (15457799)
Marta Garijo-Bufort (15457802)
Teresa Pedraz-Penalva (17415501)
Carolina Peña-González (15457808)
Isabel de la Morena (15457811)
Diego Bedoya-Sanchís (15457814)
Liliya Yankova-Komsalova (15457817)
Arantxa Conesa-Mateos (15457820)
Anna Martinez-Cristóbal (17415504)
Francisco Javier Navarro-Blasco (15457823)
Jose Miguel Senabre-Gallego (17415507)
Francisca Sivera (5079833)

November 2023

IntroductionPsoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disease. Secukinum...

Supplement_Table_S3 – Supplemental material for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Abstract

Extracted data

Supplement_Table_S3 – Supplemental material for Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

Abstract

Extracted data

Related items

Related items